Alalawy AI .2024 .Key genes and molecular mechanisms related to paclitaxel resistance. Cancer Cell Int, 24(1) : 244.
Al-Hashimi MMY .2021 .Trends in breast cancer incidence in Iraq during the period 2000-2019. , 22(12) : 3889-3896.
Alsanad SM,Howard RL,Williamson EM RL .2016 .An assessment of the impact of herb-drug combinations used by cancer patients. BMC Complement. Altern. Med, 16(1) : 393.
Basak D,Arrighi S,Darwiche Y,Deb S Y .2021 .Comparison of anticancer drug toxicities: Paradigm shift in adverse effect profile. Life, 12(1) : 48.
Daniel D and Crawford J .2006 .Myelotoxicity from chemotherapy. Seminars in Oncology, 33(1) : 74-85.
Feliu J,Heredia-Soto V,Gironés R,Jimenez-Munarriz B,Saldana J,Guillén-Ponce C,Molina-Garrido MJ C .2020 .Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin. Transl, 22 : 457-467.
Havrilesky LJ,Garfield CF,Barnett JC,Cohn DE JC .2012 .Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. Gynecol. Oncol., 125(3) : 631-634.
Khalifa MF,Pharm MF .2022 .Epidemiology of breast cancer in Baghdad City 2018. , : 1452-1456.
Ludwig H,Van Belle S,Barrett-Lee P,Birgegård G,Bokemeyer C,Gascón P,Schrijvers D .2004 .The European Cancer Anaemia Survey (ECAS): A large multinational prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur. J. Cancer, 40(15) : 2293-2306.
Nardin S,Mora E,Varughese FM,D'Avanzo F,Vachanaram AR,Rossi V,Gennari A .2020 .Breast cancer survivorship, quality of life and late toxicities. Front. Oncol., 10 : 864.
Othman RT,Abdulljabar R,Saeed A,Sadiq S,Kittani HM,Mohammed SA,Hussein NR .2011 .Cancer incidence rates in the Kurdistan Region/Iraq from. Asian Pac. J. Cancer Prev, 12(5) : 1261-64.
Pizzo PA,Poplack DG .2015 .. Principles and Practice of Pediatric Oncology. Lippincott Williams & Wilkins., : .
Salih K .1995 .Anfal: The Kurdish genocide in Iraq. , 4(2) : 24-39.
Schelenz S,Giles D,Abdallah S D .2012 .Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. , 23(7) : 1889-1893.
Takahashi S,Takei Y,Tamura K,Taneichi A,Takahashi Y,Yoshiba T,Fujiwara H T .2022 .Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage IIIC-IV ovarian cancer and poor general condition. Mol. Clin. Oncol., 16(1) : 1-7.
Testart-Paillet D,Girard P,You B,Freyer G,Pobel C,Tranchand B C .2007 .Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit. Rev. Oncol. Hematol, 63(1) : 1-11.
.2023 .National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5. US Department of Health and Human Services, : .
Vogel CL,Wojtukiewicz MZ,Carroll RR,Tjulandin SA,Barajas-Figueroa LJ,Wiens BL,Schwartzberg LS .2005 .First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J. Clin. Oncol., 23(6) : 1178-1184.
World Health .2013 .1 million new cases in 2012. Latest world cancer statistics: Global cancer burden rises to 14, : .